In Segment C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment until condition progression or even the individuals are not able to tolerate the study drugs. For all movement cytometry experiments, 10,000 cells per replicate have been analyzed, https://jamesl776alv9.hyperionwiki.com/user